Evidence map›Paper›PMID 33911072›Full record

ArticleTranslational psychiatry2021

Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer's disease.

Natalia M Lyra E Silva, Rafaella A Gonçalves, Tharick A Pascoal, Ricardo A S Lima-Filho, Elisa de Paula França Resende, Erica L M Vieira, Antonio L Teixeira, Leonardo C de Souza, Julyanna A Peny, Juliana T S Fortuna and 12 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 194 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed, 5 pooled it
25.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05050812 naunknown statusnot on this map

The Grounded Brain: How Sleeping Grounded (Earthing) Affects Cognition and Personal Perceptions in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (MCI/AD)

TypeinterventionalSponsorCalifornia Institute of Integral StudiesRan2021 to 2021Enrolled8ConditionsMild Cognitive Impairment, Chronic InflammationArmsgrounding mat
NCT07284316 phase2 / phase3active not recruitingnot on this mapstarted 2025, after this paper: background citation

Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance: A Randomized Clinical Trial

TypeinterventionalSponsorInstituto Mexicano del Seguro SocialRan2025 to 2027Enrolled100ConditionsCognitive Decline, Subjective Cognitive Impairment, Insulin ResistanceArmsTurmeric extract, Control: Placebo. 500mg gelatin in capsules 2 times a day
3 · Its place in the literature

Who cites it

194 citing papers in PubMed, 5 syntheses or guidelines pooled it, 331 citations in OpenAlex.

  1. Motor performance and its association with Alzheimer's-related biomarkers: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  17. Review
  18. Review
  19. Article
  20. Article

134 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 4 countries.

Natalia M Lyra E Silva *Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Rafaella A Gonçalves *Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Tharick A PascoalTranslational Neuroimaging Laboratory, McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Montreal, Quebec, Canada.ORCID 0000-0001-9057-8014
Ricardo A S Lima-FilhoInstitute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Elisa de Paula França ResendeBehavioral and Cognitive Neurology Research Group, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Erica L M VieiraCentre of Addiction and Mental Health (CAMH), Toronto, ON, Canada.
Antonio L TeixeiraNeuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0002-9621-5422
Leonardo C de SouzaBehavioral and Cognitive Neurology Research Group, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Julyanna A PenyInstitute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Juliana T S FortunaInstitute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Isadora C FurigoDepartment of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Debora HashiguchiDepartment of Physiology, Federal University of São Paulo, São Paulo, SP, Brazil.
Vivian S Miya-CoreixasInstitute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Julia R ClarkeSchool of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Jose F AbisambraDepartment of Neuroscience, Center for Translational Research in Neurodegenerative Disease University of Florida, Gainesville, FL, USA.
Beatriz M LongoDepartment of Physiology, Federal University of São Paulo, São Paulo, SP, Brazil.ORCID 0000-0002-2638-8061
Jose DonatoDepartment of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.ORCID 0000-0002-4166-7608
Paul E FraserTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Pedro Rosa-NetoTranslational Neuroimaging Laboratory, McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Montreal, Quebec, Canada.ORCID 0000-0001-9116-1376
Paulo CaramelliBehavioral and Cognitive Neurology Research Group, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Sergio T FerreiraInstitute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil. ferreira@bioqmed.ufrj.br.ORCID 0000-0001-7160-9866
Fernanda G De FeliceInstitute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil. felice@bioqmed.ufrj.br.ORCID 0000-0001-8358-0589
Universidade Federal do Rio de Janeiro · BRUniversidade Federal de Minas Gerais · BRDouglas Mental Health University Institute · CAUniversidade de São Paulo · BRUniversidade Federal de São Paulo · BRCentre for Addiction and Mental Health · CAInstituto de Ensino e Pesquisa Santa Casa · BRUniversity of Florida · USUniversity of Toronto · CA

Funding

PERK as a Central Mediator of Neurotoxicity in TauopathiesR01NS091329 · NINDS · UNIVERSITY OF KENTUCKY · PI ABISAMBRA, JOSE FRANCISCO · 2015 to 2019
$1.6M
NIMHD NIH HHS L32 MD009205NINDS NIH HHS R01 NS091329
6 · The paper itself

Abstract

Alzheimer's disease (AD) is associated with memory impairment and altered peripheral metabolism. Mounting evidence indicates that abnormal signaling in a brain-periphery metabolic axis plays a role in AD pathophysiology. The activation of pro-inflammatory pathways in the brain, including the interleukin-6 (IL-6) pathway, comprises a potential point of convergence between memory dysfunction and metabolic alterations in AD that remains to be better explored. Using T2-weighted magnetic resonance imaging (MRI), we observed signs of probable inflammation in the hypothalamus and in the hippocampus of AD patients when compared to cognitively healthy control subjects. Pathological examination of post-mortem AD hypothalamus revealed the presence of hyperphosphorylated tau and tangle-like structures, as well as parenchymal and vascular amyloid deposits surrounded by astrocytes. T2 hyperintensities on MRI positively correlated with plasma IL-6, and both correlated inversely with cognitive performance and hypothalamic/hippocampal volumes in AD patients. Increased IL-6 and suppressor of cytokine signaling 3 (SOCS3) were observed in post-mortem AD brains. Moreover, activation of the IL-6 pathway was observed in the hypothalamus and hippocampus of AD mice. Neutralization of IL-6 and inhibition of the signal transducer and activator of transcription 3 (STAT3) signaling in the brains of AD mouse models alleviated memory impairment and peripheral glucose intolerance, and normalized plasma IL-6 levels. Collectively, these results point to IL-6 as a link between cognitive impairment and peripheral metabolic alterations in AD. Targeting pro-inflammatory IL-6 signaling may be a strategy to alleviate memory impairment and metabolic alterations in the disease.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesAnimalsHippocampusHumansInterleukin-6MicePlaque, AmyloidAmyloid beta-PeptidesIL6 protein, humanInterleukin-6interleukin-6, mouse

Identifiers

PMID33911072
PMCPMC8080782
OpenAlexW3158545443

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.